Annual Drug Patent Expirations for STRIBILD
Stribild is a drug marketed by Gilead Sciences Inc and is included in one NDA. It is available from one supplier. There are thirteen patents protecting this drug and one Paragraph IV challenge.
Drug patent litigation for STRIBILD.
This drug has fifty-nine patent family members in twenty-nine countries.
The generic ingredient in STRIBILD is cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate. One supplier is listed for this compound. Additional details are available on the cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
